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Abstract Several highly conserved p62 homologs have recently
been isolated, e.g. the rat atypical protein kinase C-interacting
protein (ZIP), the murine A170/signal transduction and adapter
protein, and the human p62, a protein that binds the Src
homology 2 domain of p56lck. These proteins share striking
similarity in amino acid sequence and structural motifs, thereby
suggesting conserved functional properties. ZIP/p62 has been
shown to play an important role as a scaffold leading to the
activation of the transcription factor nuclear factor UB. In
addition, a nuclear form of p62 has been characterized that can
serve as a transcriptional co-activator. Moreover, p62 is capable
of binding ubiquitin (Ub) non-covalently through its Ub-
associated domain. In this review, we will focus on the structure
and function of ZIP/p62. ß 2002 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Overview
In the past several years, several genes with considerable
sequence homology have been cloned from rat, human and
mouse libraries. Zeta protein kinase C (PKC)-interacting pro-
tein (ZIP) was isolated from a rat brain cDNA library [1],
whereas a separate human p62 homolog, that binds the Src
homology 2 (SH2) domain of p56lck, was identi¢ed [2]. A170,
a gene induced by oxidative stress in mouse macrophages [3],
was cloned, as well as a cDNA for signal transduction and
adapter protein (STAP) [4]. Comparison of the amino acid
sequence between these proteins reveals that they are highly
conserved (roughly 90%) to one another (Fig. 1). The struc-
tural motifs shared by these proteins include: an SH2 binding
domain, an acidic interaction domain (AID) that binds the
atypical PKC (aPKC) [5], a ZZ ¢nger, a binding site for the
ring-¢nger protein tumor necrosis factor (TNF) receptor-as-
sociated factor 6 (TRAF6), two PEST sequences, and a ubiq-
uitin (Ub)-associated (UBA) domain (Fig. 2). The high degree
of sequence similarity between these two genes from di¡erent
sources suggests conserved functionality.
2. A growing family
2.1. ZIP
The aPKC subfamily of kinases is composed of two mem-
bers, jPKC and V/SPKC. These proteins are related with a
72% overall amino acid identity [6]. When compared to the
other isoforms, aPKCs lack the characteristic C2 domain and
are insensitive to Ca2, diacylglycerol and phorbol esters [6].
A protein that speci¢cally interacted with the regulatory do-
main of aPKCs, but not classical PKCs, was identi¢ed, and
named ZIP [1]. ZIP was isolated from a V-phage rat brain
cDNA library and is encoded by a polypeptide of 439 amino
acids. The structural motifs in ZIP include a ZZ zinc ¢nger as
a potential binding module, two PEST sequences, and a novel
putative protein binding motif, consensus sequence YX-
DEDX5SDEE/D. ZIP binds to the regulatory domain of
jPKC, comprising the pseudosubstrate site and the module
that drives interaction between ZIP and aPKC has been
mapped to amino acids 41^105 of ZIP.
Two cDNA fragments, B20 and B24, were isolated from a
rat hippocampal library screened against full length KvL2
subunits of the potassium channel [7]. B20 is identical to
ZIP cloned by Puls et al. [1], whereas B24 is a 27-amino
acid alternatively spliced form, ZIP2. Both ZIP1/ZP2 are
ubiquitously expressed, with ZIP1 displaying signi¢cantly
higher amounts than ZIP2 in non-excitable tissues, but the
ZIP1/ZIP2 ratio is closer to 1 in the central nervous system
[7]. ZIP1 interacts with both KvL2 and jPKC, thereby result-
ing in the formation of a jPKC^ZIP1^KvL2 complex. In this
complex, ZIP1 serves as a link that targets the activity of
jPKC to the KvL2 subunit of the potassium channel (Fig.
3A). ZIP1 and ZIP2 possess distinct activities in stimulating
jPKC phosphorylation of KvL2, with maximum channel
phosphorylation by jPKC occurring in the presence of ZIP1.
ZIP3, a new splice variant of the ZIP, has recently been
identi¢ed [8]. It contains a new C-terminal domain of 13 ami-
no acids starting at S221. Bicuculline insensitive GABA re-
ceptors (GABACR) are composed of three subunits and ZIP3
selectively interacts with the large intracellular loop of the
third subunit. The interaction of ZIP3 with GABACR may
form a jPKC/ZIP3/GABACR signaling complex [8], analo-
gous to the complex formed by jPKC/ZIP1/KvL2 [7].
2.2. p62, a p56lck substrate
A human ZIP homolog encoding a cytosolic 62-kDa pro-
tein (p62), with the ability to bind to the SH2 domain of
p56lck in a phosphotyrosine-independent manner, was identi-
¢ed and cloned [9]. Interestingly, p62 is capable of binding Ub
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non-covalently [10], via the presence of a UBA domain (Fig.
2, [11]).
EBIAP, a 60-kDa protein, has been found to associate with
a novel hematopoietin receptor family member induced in
B lymphocytes by Epstein^Barr virus (EBV) infection [12].
EBI3 exists on the plasma membrane of EBV-transformed
B lymphocytes, and newly synthesized EBI3 is retained in
the endoplasmic reticulum (ER) by association with calnexin,
an integral ER membrane molecular chaperone that associates
with the novel 60-kDa protein (EBIAP). Sequence alignment
reveals that EBIAP is identical to p62 [12].
2.3. Mouse STAP/A170 gene
A 60-kDa stress-induced protein was cloned from macro-
phages called A170 [3,13,14]. This protein is 97% identical to
ZIP1 and roughly 90% related to the human protein that
binds the SH2 domain of p56lck [9]. The C-terminal domain
of p62, which is completely conserved in A170, also has a⁄n-
ity for Ub [10]. The expression of A170 is regulated at both
transcriptional and post-transcriptional levels [13]. A170 is
phosphorylated by several kinases [15]. In brain, A170 can
be induced by kainate-mediated excitotoxicity [16].
A cDNA encoding a 442-amino acid protein was isolated
from a library of mouse osteoblastic cells, MC3T3-E1 [4], and
called STAP. STAP is homologous to A170 [13] and shares
97% homology with rat ZIP [1] and 90% with human p62 [9].
The STAP gene consists of eight exons and seven introns,
spanning a region of 11 kb [4]. Sequencing of the 5P £anking
region of the STAP gene revealed multiple consensus motifs
for binding of several transcription factors: two potential Sp1
binding sites, AP-1, NF-E2, MyoD, and nuclear factor UB
(NF-UB).
Fig. 1. Amino acid alignment of ZIP1, ZIP2, p62, A170 and STAP. Dots represent identical amino acids and dashes show gaps in the align-
ment.
Fig. 2. A schematic diagram showing the domain organization of the p62 protein. The general structure is common to all p62 homologs except
for ZIP2, which lacks the TRAF6 binding domain.
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3. p62’s ability to bind Ub
The ability of p62 to bind Ub non-covalently was ¢rst de-
scribed in 1996 [10]; amino acids 386^434 in the C-terminus
are required for the Ub binding property of p62. Further
studies have revealed that p62 has a⁄nity for multi-Ub chains
and may serve as a receptor to bind and store ubiquitinated
proteins [17]. A novel sequence motif of 45 amino acids is
conserved among proteins that can bind Ub, and it is referred
to as a UBA domain (Fig. 4) [11,18]. A conserved domain
alignment of amino acids in p62 which have been shown to
bind Ub [10] reveals homology to other proteins that contain
a UBA domain (Fig. 4). The structure of the UBA domain
has recently been determined by nuclear magnetic resonance
[19]. The domain forms a compact three-helix bundle, with a
hydrophobic surface on one side that is likely the target inter-
face for protein^protein interactions [19,20]. Moreover, pro-
teins which contain the UBA domain are more likely to bind
multi-Ub chains over mono-Ub [21,22]. This observation cor-
relates nicely with the presence of a UBA domain within p62
and its ability to bind multi-Ub chains [17].
4. p62 serves as a sca¡old for the NF-UB pathway
The most well-described and extensively studied function of
p62 is its role as a sca¡old for selective activation of tran-
scription factor NF-UB. The most classical form of NF-UB is
a heterodimer of p50 and p65 (Rel A), which is sequestered in
the cytosol by IUB that prevents its nuclear translocation and
activity [23]. Two IUB kinases (IKKK and IKKL) responsible
Fig. 3. p62 functional role in various signal cascades. A: p62 plays a role in recruitment of aPKC to the KvL2 subunit of the K channel
thereby leading to phosphorylation and modi¢cation of the channel [7]. B: p62 links RIP and aPKC thereby leading to phosphorylation of
IKK and activation of NF-UB upon stimulation with TNF-K. C: p62 forms a ternary complex with TRAF6 and IRAK leading to recruitment
of aPKC with subsequent phosphorylation of IKK and activation of NF-UB upon stimulation with IL-1 [22]. D: p62 serves as a bridge be-
tween p75 and TrkA neurotrophin receptors by binding TrkA and connecting p75 through interaction with TRAF6 [27]. aPKC is recruited to
the complex followed by phosphorylation and activation of IKKL.
FEBS 25774 8-2-02
T. Geetha, M.W. Wooten/FEBS Letters 512 (2002) 19^24 21
for the signal-induced phosphorylation and degradation of
IUB. The IKKs bind the NF-UB inducing kinase [24], a mem-
ber of the mitogen-activated protein kinase kinase family that
interacts with TRAF2 [25], linking IUB degradation and NF-
UB activation to the TNF receptor complex. aPKCs bind to
the IKKs in vivo and in vitro [26], whereby jPKC selectively
phosphorylates and activates IKKL.
The association of p62 with aPKC provides a sca¡old for
the NF-UB pathway in both the TNF-K and interleukin-1 (IL-
1) receptor signaling pathway [27^29]. In the TNF signaling
cascade, TRAF2 and RIP simultaneously bind to TRADD,
and the coiled-coil region of RIP interacts with the zinc ¢nger
(ZZ) of p62. The aPKC interaction domain (AID) of p62
interacts with the V1 domain of the aPKCs and serves to
recruit jPKC to the receptor signaling complex (Fig. 3B).
The mechanism by which the aPKCs are activated in these
complexes remains unknown. On stimulation of the IL-1 re-
ceptor the intracellular domain interacts with TIR domain of
MyD88, a functional analog of TRADD [30,31]. MyD88 then
binds IRAK which recruits TRAF6, followed by recruitment
of p62. The interaction of TRAF6 with p62 in either the
TNF-K (Fig. 3B) or IL-1 (Fig. 3C) signaling cascades is re-
quired for NF-UB activation [27,28].
Recently a requirement for multi-Ub chains in the activa-
tion of the NF-UB pathway by TRAF6 [32], a recently de-
scribed E3 Ub ligase [33], has been documented. Since p62
possesses a UBA domain (Fig. 4), which displays a preference
for multi-Ub chains [17,21], it is possible that p62 may regu-
late activation of NF-UB through recognition of TRAF6-cat-
alyzed multi-Ub chains [34].
Nerve growth factor (NGF) binds to both p75 and TrkA
neurotrophin receptors leading to activation of the transcrip-
tion factor NF-UB [35]. Previous work in our lab has shown
that p62 binds TrkA selectively, and interacts with p75
through TRAF6 [36]. Upon NGF stimulation, the interaction
between TRAF6 and p62 occurs before p62 binds the TrkA
receptor, suggesting that p62 interacts with TRAF6 to then
link p75 and TrkA receptors (Fig. 3D). p62 then recruits
aPKC, which phosphorylates IKKL, leading to the activation
of NF-UB. In PC12 cells expressing both receptors, transfec-
tion of antisense p62 inhibits NGF-induced NF-UB activation
[36]. Therefore, p62 serves as a bridge that sca¡olds together
both p75 and TrkA receptors for NF-UB activation and sur-
vival signaling [36]. ZIP2 fails to activate NF-UB [36], since it
lacks the TRAF6 binding domain [28]. In this regard, ZIP2
serves as an endogenous dominant negative regulator of NF-
UB activation.
5. Subcellular localization of p62
5.1. A role for p62 in the nucleus
Chicken ovalbumin upstream promoter transcription factor
(COUP-TF), an orphan member of the nuclear hormone re-
ceptor subfamily, includes COUP-TFI and COUP-TFII [37].
The DNA binding domain of COUP-TF contains two Sp1
binding sites, which have been proposed to serve as docking
sites [38]. Interestingly, jPKC has been shown to bind and
phosphorylate Sp1 [39^41]. The orphan receptor co-activator
(ORCA) binds COUP-TF in vitro and allows COUP-TF to
act as a transcriptional activator in mammalian cells [42].
ORCA is identical to the 62-kDa protein that binds to tyro-
sine kinase signaling molecule p56lck [2]. Given the interac-
tions between aPKCs/p62 [1], COUP-TFII^p62 [42], and
aPKC^Sp1 [39], we speculate that a complex may be formed,
in which aPKC regulates transcription directly or indirectly.
Additionally, p62 has been shown to stimulate transcription
Fig. 4. Alignment of the UBA domain of p62 with proteins containing known UBA domains [18]. The UBA domain (amino acids 374^413) of
p62 was subjected to a conserved domain sequence alignment (NCBI-CD search). gi = GenInfo Identi¢er.
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of reporter genes linked to the enhancer of simian virus 40
(SV40) [43]. p62 does not bind to the SV40 enhancer on its
own, but appears to act in conjunction with cellular factors to
indirectly modulate transcription. Recent ¢ndings suggest that
the localization of p62 to the nucleus may be signal-regulated.
For example, stimulation of HeLa cells with sorbitol results in
localization of p62 into the nucleus [44]. However, p62 does
not appear to possess any of the classical nuclear localization
signal (NLS) [45]. Treatment of cells with leptomycin B, an
inhibitor of nuclear export, drives accumulation of p62 within
the nucleus, suggesting the presence of a nuclear export signal.
We speculate that p62 shuttles into the nucleus bound to
aPKC, which is known to possess a functional NLS [46].
This would be in keeping with the ability of aPKCs to regu-
late the localization of ZIP/p62 [1]. Once localized into the
nucleus, p62 directly co-associates with chromatin [45], further
suggesting a role in regulating gene transcription [42,43].
5.2. Vesicle and inclusion body localization
In the lysosome-targeted endosome, endogenous and ec-
topically expressed p62 co-localizes with both endogenous V/
SPKC and jPKC [47,48]. Additionally, p62 co-localizes with
the receptor for epidermal growth factor (EGF) in activated
cells, whereas impaired activation of aPKC enzyme activity
has been observed to severely impair the endocytic membrane
tra⁄cking of the EGF receptor and transport of internalized
EGF receptors to the endosome [47]. p62 also binds the NGF
receptor, TrkA [48], which localizes to the endosomal^lyso-
somal network. Inhibition of p62 expression has been shown
to block NGF-induced neurite outgrowth [48]. Since delivery
of TrkA^NGF receptor is required for neurite outgrowth, it is
possible that p62, via its interaction with TrkA as well as
other receptors, may be capable of directing their localization
to the endosome.
Recently, p62 immunoreactivity has been observed in neu-
ronal and glial Ub-containing inclusions in Alzheimer’s,
Pick’s, Parkinson’s, dementia with Lewy bodies, and multiple
system atrophy [49,50]. Also, p62 has been identi¢ed as a
major constituent of intracytoplasmic hyaline bodies [51]. Ac-
cumulation of p62 in these cells may be due to recognition of
multi-ubiquitinated proteins by p62. Ub-dependent and -inde-
pendent mechanisms could contribute to the deposition of p62
in neuronal and glial inclusions [50^52]. The presence of p62
in protein aggregates in vivo, and the induction of p62 ex-
pression in neuronal cells in vitro suggest that p62 may play a
role in the pathogenesis of a number of neurodegenerative
diseases, where faulty destruction of ubiquitinated proteins
leads to the formation of cellular inclusions symptomatic of
the pathology of the disease (reviewed in [53]).
6. Summary
The amino acid sequences and the structural motifs shared
by all of the p62 genes suggest a high degree of conserved
function among members of this family (Figs. 1^3). The abil-
ity of p62 to bind Ub through its UBA domain (Fig. 4), and
to reside in both the nucleus as well as to tra⁄c receptors,
suggests that p62 serves a complex role in uniting receptor-
mediated signaling events to ubiquitination.
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